BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 25528358)

  • 1. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.
    Narisety SD; Frischmeyer-Guerrerio PA; Keet CA; Gorelik M; Schroeder J; Hamilton RG; Wood RA
    J Allergy Clin Immunol; 2015 May; 135(5):1275-82.e1-6. PubMed ID: 25528358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness.
    Orgel K; Burk C; Smeekens J; Suber J; Hardy L; Guo R; Burks AW; Kulis M
    Clin Exp Allergy; 2019 Apr; 49(4):461-470. PubMed ID: 30383313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of a probiotic with peanut oral immunotherapy: A randomized trial.
    Tang ML; Ponsonby AL; Orsini F; Tey D; Robinson M; Su EL; Licciardi P; Burks W; Donath S
    J Allergy Clin Immunol; 2015 Mar; 135(3):737-44.e8. PubMed ID: 25592987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
    Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
    Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allergen-specific oral immunotherapy for peanut allergy.
    Nurmatov U; Venderbosch I; Devereux G; Simons FE; Sheikh A
    Cochrane Database Syst Rev; 2012 Sep; (9):CD009014. PubMed ID: 22972130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
    Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC
    Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.
    Vickery BP; Scurlock AM; Kulis M; Steele PH; Kamilaris J; Berglund JP; Burk C; Hiegel A; Carlisle S; Christie L; Perry TT; Pesek RD; Sheikh S; Virkud Y; Smith PB; Shamji MH; Durham SR; Jones SM; Burks AW
    J Allergy Clin Immunol; 2014 Feb; 133(2):468-75. PubMed ID: 24361082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of allergen-specific immunotherapy for peanut allergy: a meta-analysis of randomized controlled trials.
    Sun J; Hui X; Ying W; Liu D; Wang X
    Allergy Asthma Proc; 2014; 35(2):171-7. PubMed ID: 24717795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial.
    Fleischer DM; Burks AW; Vickery BP; Scurlock AM; Wood RA; Jones SM; Sicherer SH; Liu AH; Stablein D; Henning AK; Mayer L; Lindblad R; Plaut M; Sampson HA;
    J Allergy Clin Immunol; 2013 Jan; 131(1):119-27.e1-7. PubMed ID: 23265698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective.
    Vickery BP; Berglund JP; Burk CM; Fine JP; Kim EH; Kim JI; Keet CA; Kulis M; Orgel KG; Guo R; Steele PH; Virkud YV; Ye P; Wright BL; Wood RA; Burks AW
    J Allergy Clin Immunol; 2017 Jan; 139(1):173-181.e8. PubMed ID: 27522159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization.
    Kim EH; Yang L; Ye P; Guo R; Li Q; Kulis MD; Burks AW
    J Allergy Clin Immunol; 2019 Nov; 144(5):1320-1326.e1. PubMed ID: 31493887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial.
    Burks AW; Wood RA; Jones SM; Sicherer SH; Fleischer DM; Scurlock AM; Vickery BP; Liu AH; Henning AK; Lindblad R; Dawson P; Plaut M; Sampson HA;
    J Allergy Clin Immunol; 2015 May; 135(5):1240-8.e1-3. PubMed ID: 25656999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children.
    Kim EH; Keet CA; Virkud YV; Chin S; Ye P; Penumarti A; Smeekens J; Guo R; Yue X; Li Q; Kosorok MR; Kulis MD; Burks AW
    J Allergy Clin Immunol; 2023 Jun; 151(6):1558-1565.e6. PubMed ID: 36828080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, Safety, and Quality of Life in a Multicenter, Randomized, Placebo-Controlled Trial of Low-Dose Peanut Oral Immunotherapy in Children with Peanut Allergy.
    Blumchen K; Trendelenburg V; Ahrens F; Gruebl A; Hamelmann E; Hansen G; Heinzmann A; Nemat K; Holzhauser T; Roeder M; Rosenfeld L; Hartmann O; Niggemann B; Beyer K
    J Allergy Clin Immunol Pract; 2019 Feb; 7(2):479-491.e10. PubMed ID: 30423449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and efficacy of sublingual and oral immunotherapy for milk allergy.
    Keet CA; Frischmeyer-Guerrerio PA; Thyagarajan A; Schroeder JT; Hamilton RG; Boden S; Steele P; Driggers S; Burks AW; Wood RA
    J Allergy Clin Immunol; 2012 Feb; 129(2):448-55, 455.e1-5. PubMed ID: 22130425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy.
    Patil SU; Steinbrecher J; Calatroni A; Smith N; Ma A; Ruiter B; Virkud Y; Schneider M; Shreffler WG
    J Allergy Clin Immunol; 2019 Nov; 144(5):1310-1319.e4. PubMed ID: 31377342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of the immunologic response to peanut during immunotherapy is often transient.
    Gorelik M; Narisety SD; Guerrerio AL; Chichester KL; Keet CA; Bieneman AP; Hamilton RG; Wood RA; Schroeder JT; Frischmeyer-Guerrerio PA
    J Allergy Clin Immunol; 2015 May; 135(5):1283-92. PubMed ID: 25542883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose oral immunotherapy for children with anaphylactic peanut allergy in Japan.
    Nagakura KI; Yanagida N; Sato S; Nishino M; Asaumi T; Ogura K; Ebisawa M
    Pediatr Allergy Immunol; 2018 Aug; 29(5):512-518. PubMed ID: 29603410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on peanut allergy: Prevention and immunotherapy.
    Cook QS; Kim EH
    Allergy Asthma Proc; 2019 Jan; 40(1):14-20. PubMed ID: 30582491
    [No Abstract]   [Full Text] [Related]  

  • 20. Feasibility of desensitizing children highly allergic to peanut by high-dose oral immunotherapy.
    Reier-Nilsen T; Michelsen MM; Lødrup Carlsen KC; Carlsen KH; Mowinckel P; Nygaard UC; Namork E; Borres MP; Håland G
    Allergy; 2019 Feb; 74(2):337-348. PubMed ID: 30225844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.